New Release – Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial
Only CEP Trial Designed as a Superiority Trial using DW-MRI to Demonstrate Effectiveness Against the Currently Approved Sentinel Device
Allgemein
New Release – Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors
Financing and Reinforcement of Board of Directors Builds Momentum in Readiness for the Initiation of the IDE Pivotal Trial
New Release – Final data from European PROTEMBO C Trial Published in EuroIntervention Journal
New published European clinical evidence builds momentum for the FDA approved Pivotal PROTEMBO clinical trial.
New Release – Protembis Announces FDA Approval of its Pivotal Investigational Device Exemption (IDE) Study
Novel Adaptive Superiority Trial Design of ProtEmbo® Cerebral Embolic Protection (CEP) System
News Release – Professor J Mocco to Join Protembis’ Board of Directors
Protembis announces the appointment of Professor J. Mocco to Board of Directors
News Release – Azin Parhizgar As New Chairwoman of Protembis
Azin Parhizgar To Chair Protembis’ New Board of Directors
News Release – EU Clinical Study
Protembis announces completion of 20 cases in European CE mark study with the ProtEmbo® Cerebral Protection System Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland Aachen, Germany, February 25, 2021 Protembis GmbH, a privately held emerging medical device company, announced today the successful completion … Weiterlesen …
News Release – Series A Financing
Aachen-based Startup Company Protembis Successfully Closes $ 10 Million Series A Financing
News Release – ISO 13485:2016
Protembis Achieves ISO 13485:2016 Quality Management System Certification